TYK2 and hematopoietic and lymphoid cell neoplasm: Genomic, transcriptomic and proteomic assays have led to identification of tyrosine kinase 2 (TYK2) mutations, fusion proteins and expression changes in a variety of hematological cancers, carcinomas and soft-tissue sarcomas [4].